Thyroid/Thyroid cancer Flashcards

(88 cards)

1
Q

ATA nodule criteria for biopsy

A

high - 1cm
intermediate - 1cm
low - 1.5cm
very low - 2.0cm

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

TR nodule criteria for biopsy

A

TR 3 - 2.5cm
TR 4 - 1.5cm
TR 5 - 1.0cm

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

which Bethesda do we send for Thyroseq

A

Bethesda 3,4,5

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Bethesda categories

A
1 - nondiagnostic
2- benign
3 - AUS/FLUS
4 - follicular neoplasm
5 - suspicious
6 - malignant
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

malignancy risk in high suspicion nodules

A

70-90%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

malignancy risk in intermediate suspicion nodules

A

10-20%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

malignancy risk in low suspicion nodules

A

5-10%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

malignancy risk in very low suspicion nodules

A

<3%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

malignancy risk in benign nodules

A

< 1%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

high risk US features

A
microcalcification
irregular margin
taller than wide
ETE
interrupted rim calcification
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

malignancy risk of AUS/FLUS (Bethesda 3)

A

5-15%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

malignancy risk of follicular neoplasm (Bethesda 4)

A

15-30%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

malignancy risk of benign nodule (Bethesda 2)

A

0-3%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

which Bethesda category is Hurthle cell neoplasm

A

Bethesda 4

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

repeated nondiagnostic FNA with high risk features

A

surgery or close US observation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

pathologic criteria for sufficient thyroid FNA

A

6 groups of well-visualized follicular cells, each containing at least 10 well-preserved epithelial cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

malignancy risk in nondiagnostic samples

A

low

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

appropriate operation for indeterminant thyroid nodules

A

lobectomy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

high suspicion nodule with negative FNA

A

repeat FNA within 12 months

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

intermediate nodules with negative FNA

A

repeat US 12-24 months with repeat FNA if > 50% volumetric growth

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

very low suspicion nodule with negative FNA

A

repeat US 24 months

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

risk of thyroid cancer after 2 negative FNA

A

essentially 0%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

risk of false negative FNA

A

3%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

what % of adults have thyroid nodules

A

50%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
recommendation for thyroid nodules with suspected iodine deficiency
150 mcg daily iodine
26
management of thyroid nodules > 4cm
symptomatic - surgery FNA negative FNA - surgery or follow
27
thyroid nodule discovered during pregnancy
FNA if euthyroid or hypothyroid
28
PTC diagnosed during pregnancy
``` if substantial growth or e/o lymph nodes - surgery if stable (ie no growth), surgery after delivery ```
29
suspicious lymph node size criteria for FNA
8-10mm in SHORTEST dimension
30
absolute criteria of total thyroidectomy
thyroid cancer > 4cm gross ETE clinically apparent metastatic disease to nodes or distant sites
31
surgery for 1-4cm thyroid cancers
lobectomy or total thyroidectomy
32
therapeutic central neck dissection for which patients
clinically involved central nodes
33
prophylactic central neck dissection (ipsilateral or bilateral) should be considered in which patients
PTC with no clinical nodes who have advanced primary tumors (T3 or T4), or clinically involved lateral neck nodes
34
who does NOT need prophylactic central neck dissection
small (T1 or T2) tumors, noninvasive, clinically node-negative PTC, and for most follicular cancers
35
who should have therapeutic lateral neck lymph node dissection
ONLY biopsy-proven metastatic lateral cervical adenopathy
36
surgery for most follicular carcinomas
lobectomy
37
role of RAI ablation of remaining lobe in lieu of completion thyroidectomy
not recommended
38
diurnal pattern of TSH
highest values in late afternoon/evening
39
binding globulins for thyroid T4/T3
TBG transthyretin albumin
40
what percentage of T4 and T3 are bound
99.7 % +
41
two different assays for free hormone testing
``` analogue (cheaper, easier) equilibrium dialysis (not affected by serum binding proteins) ```
42
deiodinase D1 converts T4 to T3 in which organs
liver, kidney
43
deiodinase D2 converts T4 to T3 in which organ
brain
44
reverse T3 (RT3) affinity for the T3 receptor
100x less than T3
45
major disorders of thyroid hormone binding proteins
pregnancy estrogen use congenital TBG excess familial dysalbuminemic hyperthyroxinemia
46
what is familial dysalbuminemic hyperthyroxinemia
inherited disorder in which albumin has enhanced affinity for T4, resulting in increased TOTAL T4 but not T3
47
role of T3 resin uptake measurement
helps distinguish protein binding disorders from true thyroid disease (inversely proportional to the protein binding capacity)
48
t3 resin uptake in hyperthyroidism
high
49
t3 resin uptake in hypothyroidism
low
50
two conditions where thyroglobulin can be useful
thyroid cancer | thyroiditis
51
effect of biotin on thyroid function tests
low TSH high T4 looks like hyperthyroidism
52
when to suspect HAMA (heterophile ab) interference
abnormal TFTs that don't fit clinical scenario
53
indications to treat subclinical hyperthyroidism
``` age > 65 years TSH <0.1 symptomatic bone disease/afib 0.1-0.4 can be considered for therapy ```
54
when to repeat thyroid US for 1cm very low risk thyroid nodules
either no follow up, or 2 years
55
initial surgical procedure for differentiated thyroid cancer with tumor > 4cm?
total thyroidectomy
56
initial surgical procedure with clinically apparent nodal mets, distant mets, or with gross extrathyroidal extension?
total thyroidectomy
57
initial surgical procedure for thyroid cancer > 1cm and < 4cm without ETE, and without nodal mets?
either lobectomy or total thyroidectomy
58
which patients should have therapeutic central compartment dissection?
pts with clinically involved central nodes
59
which patients should be considered for prophylactic central-compartment neck dissection (ipsilateral or bilateral)?
PTC with clinically uninvolved central compartment nodes BUT T3 or T4 tumors or clinically involved lateral neck nodes
60
which patients do NOT need prophylactic central neck dissection?
small tumors (T1, T2), noninvasive, node-negative PTC and most follicular cancers
61
which patients should get lateral neck lymph node dissection?
biopsy proven nodal metastasis
62
which patients should be offered completion thyroidectomy?
those for whom total thyroidectomy would have been recommended had the diagnosis been available before initial surgery (ie gross ETE, nodal involvement)
63
T1a
tumor < 1cm, without ETE
64
T1b
1-2cm, without ETE
65
T2
2-4cm, without ETE
66
T3
> 4cm in thyroid, OR | any size tumor with minimal ETE (sternohyoid muscle, perithyroid soft tissues)
67
T4a
tumor of any size extending thyroid capsule to invade subQ tissue, larynx, trachea, esophagus, or recurrent laryngeal nerve
68
T4b
tumor of any size involving prevertebral fascia or encasing carotid artery or mediastinal vessels
69
N0
no metastatic nodes
70
N1a
mets to level 6 nodes
71
N1b
mets to nodes in all other levels
72
M0
no distant mets
73
M1
distant mets
74
patient with thyroid cancer on levothyroxine withdrawal for treatment of thyroid cancer who develops nausea, confusion, lethargy, weakness, headache
check sodium level
75
number and size of micrometastases that still qualify as low-risk thyroid cancer
< or = 5, less than 0.2mm in largest dimension
76
TSH goal for low-risk thyroid cancers
0.5-2.0
77
TSH goal for intermediate-risk thyroid cancers
0.1-0.5
78
TSH goal for high-risk thyroid cancers
< 0.1
79
most common cause of thyroid storm in a patient already on thionamide tx
medication noncompliance
80
rising calcitonin/CEA in MTC patient with negative imaging -- where to look for mets
Liver MRI with contrast MRI spine FDG PET/DOTATATE can be considered but not used routinely
81
2 ways of differentiating destructive thyroiditis from Graves'
uptake/scan, serum thyroglobulin
82
Graves' pt gets RAI, has worsening hyperthyroidism the following week. Likely diagnosis?
destructive thyroiditis due to RAI
83
Graves' pt gets RAI, then develops hyperthyroidism again a month later. Likely diagnosis?
recurrent Graves' due to insufficient RAI dose
84
Graves' pt gets RAI, then becomes more hyperthyroid after. How to differentiate between thyroiditis and recurrent Graves'?
uptake/scan
85
Pt with PTC has rising Tg level, negative Tg Abs, and negative whole body scan and neck US. Next imaging test?
PET/CT
86
treatment for pregnant female with substantial volume of residual cancer
surgery in 2nd trimester
87
treatment for pregnant female with small thyroid cancer
surgery after delivery
88
most common immune checkpoint inhibitor side effect
hypothyroidism